Last reviewed · How we verify
Advair 250
Advair 250 combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.
Advair 250 combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Advair 250 |
|---|---|
| Also known as | fluticasone/salmeterol 250/50 |
| Sponsor | Milton S. Hershey Medical Center |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing sustained bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.
Approved indications
- Asthma maintenance treatment
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Nervousness
- Oral candidiasis
- Palpitations
Key clinical trials
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma (PHASE3)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) (PHASE3)
- Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID (PHASE4)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (PHASE1)
- Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |